Category Archives: Social media and healthcare

Is regulatory and legal blocking pharma’s social media marketing ?

images-1KEY IDEA: 72% of online U.S. Adults have looked for health information online in the past year,  and a similar proportion of European online consumers are social health users.  Moreover, a recent study found that adoption of physician-only social networks by European doctors almost doubled in 2012. Should pharma companies engage with their audiences and become part of the conversation and what are the barriers to using social media marketing for pharma? Continue reading

Patient engagement and DTC marketing

Avoiding a Pitfall - Arrow Man Jumps Over HoleKEY TAKEAWAY: 30% of social media users prefer social care to phoning customer service and this is happening across age groups and income brackets: 17% of people older than 55 prefer social media over the telephone for service, and nearly half of people earning more than $200k per year prefer social media over live interactions for customer service. Continue reading

Pharma and social media: A qualitative look

analysis social mediaKEY TAKEAWAY: Analysis of two social media accounts, Twitter and Pinterest, show that the majority of followers were either industry people (media, agencies) and that patent followers were not engaging with the pharma brand. However levels of engagement vary by condition. Continue reading

Social media and pharma marketing

mouseecg50-300x300Post Summary: While the use of social media by consumers has been increasing the FDA still has not issued social media marketing guidelines but even without these guidelines pharma marketers have to ask the question “do patients really want us as part of the conversation?”.  In conducting qualitative research on the use of social media in healthcare decisions by patients we found that the use of social media varies by condition and patient population.  However, social media can provide drug marketers with invaluable real time insights into patient populations. Continue reading

Can pharma companies regain the trust of a skeptical public ?

An article in the LA Times suggested that patients should not necessarily trust newly approved drugs because the data in the clinical trials might tell the whole story.  While the move by GSK to open the books on clinical trials is a good one transparency has to be an accepted way of doing business for biopharma. Continue reading